Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohns disease

European Journal of Clinical Nutrition

Volumn 66, Issue 11, 2012, Pages 1219-1223

  Sazuka, S ^a   Katsuno, T ^a   Nakagawa, T ^a   Saito, M ^a   Saito, K ^a   Matsumura, T ^a   Arai, M ^a   Sato, T ^a   Yokosuka, O ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Crohn's disease (CD); enteral nutrition (EN); infliximab (IFX); loss of response

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLON CROHN DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG DOSE INCREASE; ELEMENTAL DIET; ENTERIC FEEDING; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; REMISSION; RETROSPECTIVE STUDY; SMOKING HABIT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG TOLERANCE; ENTERAL NUTRITION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; REFERENCE VALUES; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84868644208     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2012.120     Document Type: Article

References (30)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317.
2. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474: 298-306.
3. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
4. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011; 140: 1827-1837; e1822.
5. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011; 33: 857-869.
6. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
7. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
8. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885.
9. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-767.
10. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-995.
11. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011; 34: 1-10.
12. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.
13. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-1231.
14. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
15. Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011; 33: 349-357.
16. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000; 43: S85-S93.
17. Tanaka T, Takahama K, Kimura T, Mizuno T, Nagasaka M, Iwata K et al. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease. J Gastroenterol Hepatol 2006; 21: 1143-1149.
18. Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 307-320.
19. Griffiths AM. Enteral nutrition in the management of Crohn's disease. J Parenter Enteral Nutr 2005; 29: S108-S112discussion S112-107, S184-108.
20. Lochs H. Enteral nutrition-the new maintenance therapy in Crohn's disease? Inflamm Bowel Dis 2007; 13: 1581-1582.
21. Rigaud D, Cosnes J, Le Quintrec Y, Rene E, Gendre JP, Mignon M. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut 1991; 32: 1492-1497.
22. Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 2000; 95: 735-739.
23. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997; 41: 487-493.
24. Tsune I, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Takei Y et al. Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology 2003; 125: 775-785.
25. Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 2009; 136: 564-574; e562.
26. Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55: 356-361.
27. Korelitz BI. The role of liquid diet in the management of small bowel Crohn's disease. Inflamm Bowel Dis 2000; 6: 66-67; discussion 68-69.
28. Hirakawa H, Fukuda Y, Tanida N, Hosomi M, Shimoyama T. Home elemental enteral hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn's disease. Gastroenterol Jpn 1993; 28: 379-384.
29. Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn's disease. J Gastroenterol 1995; 30(Suppl 8): 83-87.
30. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther 2006; 24: 1333-1340.